Neurological Institute Outcomes
Multiple Sclerosis
Multiple Sclerosis - Focus on Mental Health
Depression is commonly observed in people with MS, with approximately 25% to 50% of all patients being affected.¹ Depression, whether diagnosed or not, can correlate with decreased adherence to prescribed treatments for MS.² Treatment for depression can include pharmacotherapy, psychotherapy, or cognitive behavioral therapy.³ Treating depression can improve disease modifying therapy adherence, fatigue, and quality of life.³
Patients With Depression Screening by PHQ-9
2020 – 2021
In 2021, 77.7% (N = 1981) of patients were screened for depression by PHQ9.
Patients With Concern for Depression (PHQ-9 ≥ 10)
2020 – 2021
In 2021, 28.1% (N = 717) of screened patients had PHQ9 scores concerning for depression (PHQ9 ≥ 10).
Patients Treated With Pharmacotherapy or Psychotherapy
2020 – 2021
In 2021, 66.3% (N = 475) of the patients with PHQ9 scores concerning for depression were treated with pharmacotherapy or psychotherapy.
